Viewing Study NCT02534935


Ignite Creation Date: 2025-12-24 @ 10:44 PM
Ignite Modification Date: 2026-03-09 @ 1:59 AM
Study NCT ID: NCT02534935
Status: COMPLETED
Last Update Posted: 2021-09-27
First Post: 2015-02-23
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
Sponsor: Pfizer
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Meningococcal B Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase 2 Immunogenicity View
None Safety View
None Tolerability Study View
None rLP2086 Vaccine View
None Healthy Toddlers View
None Neisseria meningitidis View
None Duration of Immunogenicity View